Navigation Links
Anadys Pharmaceuticals to Present at Bio Investor Forum
Date:10/27/2008

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 7th annual BIO Investor Forum on Thursday, October 30, 2008 at 1:45 p.m. PDT (4:45 p.m. EDT) at the Palace Hotel in San Francisco, California.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and an update on its development programs.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through November 13, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
2. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
3. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
4. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
5. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
6. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
7. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
10. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... , ... America Walks , a national advocacy organization that promotes walking ... of Pittsburgh Graduate School of Public Health , has been awarded a Walking ... from around the country to participate in a four-month training program designed to strengthen ...
(Date:5/25/2016)... IN (PRWEB) , ... May 25, 2016 , ... ... group health insurance, has seen a significant spike in their clients' employee participation ... their annual biometric health screening by implementing a high-deductible health plan with outcome-based ...
(Date:5/25/2016)... GA (PRWEB) , ... May 25, 2016 , ... ... solutions builder, has announced that it will join America's leading engineers at the ... be held at the Georgia World Congress Center. , Engineers, speakers and ...
(Date:5/24/2016)... Slidell, LA (PRWEB) , ... May 24, 2016 , ... ... which will feature a unique and patented refillable hanging wipe dispenser. The campaign kick-off ... 1, 2016 and will end June 25, 2016. The goal is to raise $1,000 ...
(Date:5/24/2016)... ... May 24, 2016 , ... Fire Door Solutions, ... one resource, from start to finish, for Life Safety compliance. These expanded ... surveys requested by the Joint Commission, and fire stopping reviews, inspections, and repairs. ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016  Diana Russell suffers from a form of ... inside out.  This disease has put her in a ... and grandchildren to leave her home.  Because of the ... haul the wheelchair.  So if there is a family ... is left to wait for the bus. ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice ... officer, today. In his new role, Marziani will lead the company,s business development and ... to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... OXFORD, England , May 24, 2016 ... Practice and Education in Clinical Neurophysiology  ... medical information products and services, today announced the launch ... , an open access journal that focuses on clinical ... latest research, case reports, clinical series, normal values and ...
Breaking Medicine Technology: